Literature DB >> 32654534

Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways.

Mohammad Mohammadi1, Roghayeh Abbasalipourkabir1, Nasrin Ziamajidi1,2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is associated with lipid accumulation and lipotoxicity. The main aim of this study is to evaluate the synergistic treatment effect of fish oils (FOs) and chicoric acid (CA) in palmitate (PA)-induced NAFLD HepG2 model. HepG2 cells were pre-treated with palmitate (0.75 mM) for 24 h, and then were exposed to CA, FOs and combination of these chemicals for another 24 h. Gene expression and protein levels were determined using qRT-PCR and western blotting or ELISA analysing, respectively. The combination index (CI) values of FOs and CA in HepG2 cells were calculated according to the Chou-Talalay equation using the CompuSyn software. FOs and CA acid together synergistically reduced lipid accumulation as indicated by decreased oil red O staining (vehicle-treated control: 1 ± 0.1; PA-treated control: 4.7 ± 0.4; PA + CA100: 3.9 ± 0.4; PA + CA200: 2.4 ± 0.3; PA + FOs: 2.7 ± 0.1; PA + CA200 + FOs: 1.5 ± 0.1) and triglyceride (vehicle-treatedcontrol:10 ± 1.2; PA-treated control: 25.8 ± 2.7; PA + CA100: 18.9 ± 2.5; PA + CA200: 14.4 ± 1.8; PA + FOs: 15.2 ± 2.4; PA + CA200 + FOs: 11.9 ± 1.5) levels in PA-treated HepG2 cells. Gene expression and Immunoblotting analysis confirmed the combination effect of FOs and CA in up-regulation of AMPK-mediated PPARα/UCP2 and down-regulation of AMPK-mediated SREBP-1/FAS signalling pathways. Collectively, these results suggest that combining FOs with CA can serve as a potential combination therapy for NAFLD.

Entities:  

Keywords:  AMPK; Fish oil; PPARα; SREBP-1c; chicoric acid; palmitate

Year:  2020        PMID: 32654534     DOI: 10.1080/13813455.2020.1789881

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  6 in total

1.  The effect of omega3 fatty acid supplementation on PPARγ and UCP2 expressions, resting energy expenditure, and appetite in athletes.

Authors:  Sara Moradi; Mohamadreza Alivand; Yaser KhajeBishak; Mohamad AsghariJafarabadi; Maedeh Alipour; Philip D Chilibeck; Beitullah Alipour
Journal:  BMC Sports Sci Med Rehabil       Date:  2021-05-08

Review 2.  Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates.

Authors:  Noel Salvoza; Pablo J Giraudi; Claudio Tiribelli; Natalia Rosso
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

Review 3.  Chicoric Acid: Natural Occurrence, Chemical Synthesis, Biosynthesis, and Their Bioactive Effects.

Authors:  Min Yang; Chao Wu; Tianxi Zhang; Lei Shi; Jian Li; Hongbao Liang; Xuzhen Lv; Fengtang Jing; Lu Qin; Tianlun Zhao; Chenxi Wang; Guangxu Liu; Shuai Feng; Feng Li
Journal:  Front Chem       Date:  2022-06-23       Impact factor: 5.545

4.  Paeoniflorin alleviates liver injury in hypercholesterolemic rats through the ROCK/AMPK pathway.

Authors:  Tong Liu; Ning Zhang; Lingya Kong; Sijie Chu; Ting Zhang; Guangdi Yan; Donglai Ma; Jun Dai; Zhihong Ma
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

5.  Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NFκB Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice.

Authors:  Xiaoqin Ding; Tunyu Jian; Jiawei Li; Han Lv; Bei Tong; Jing Li; Xiuhua Meng; Bingru Ren; Jian Chen
Journal:  Oxid Med Cell Longev       Date:  2020-11-03       Impact factor: 6.543

6.  Divergent Metabolic Effects of Metformin Merge to Enhance Eicosapentaenoic Acid Metabolism and Inhibit Ovarian Cancer In Vivo.

Authors:  Mary P Udumula; Laila M Poisson; Indrani Dutta; Nivedita Tiwari; Seongho Kim; Jasdeep Chinna-Shankar; Ghassan Allo; Sharif Sakr; Miriana Hijaz; Adnan R Munkarah; Shailendra Giri; Ramandeep Rattan
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.